Humana Surpasses Quarterly Estimates but Sticks to Modest 2026 Profit Outlook
Despite exceeding quarterly earnings expectations, Humana's cautious profit forecast has left some analysts underwhelmed amid rising industry hopes.
Humana Beats Quarterly Estimates but Sticks to Conservative 2026 Profit Outlook
Despite surpassing quarterly expectations, Humana's unchanged profit forecast has left some analysts underwhelmed amid soaring industry hopes.
Humana Surpasses Quarterly Estimates But Sticks to Cautious Profit Outlook Amid Market Expectations
Despite exceeding quarterly earnings forecasts, Humana's reaffirmation of its 2026 profit guidance has left some analysts underwhelmed amid the...
FedEx Leverages GLP-1 Boom to Strengthen Healthcare Logistics Business
As demand for GLP-1 medications surges, FedEx is strategically enhancing its healthcare logistics capabilities to tap into the growing B2B market.
FedEx Targets GLP-1 Market Surge with Strategic Healthcare Logistics Expansion
As the demand for GLP-1 medications skyrockets, FedEx is prioritizing its healthcare logistics services to tap into the lucrative...
FedEx Targets Healthcare Logistics Growth Amid GLP-1 Surge
As the demand for GLP-1 medications rises, FedEx is strategically enhancing its healthcare logistics services to capitalize on a booming...
Stocks in the Spotlight: AI Winners and Losers Since Last Month
Ahead of the CNBC Investing Club's July Monthly Meeting, we analyze the three stocks that surged during the AI rally and the three that have...
"Market Movements: Top AI Stock Performers Shine While Others Dim Before July Meeting"
As the CNBC Investing Club prepares for its July Monthly Meeting, we analyze the standout stocks that surged with the AI boom and those that lost...
"Navigating the AI Wave: Top and Bottom Stock Performers Ahead of July Monthly Meeting"
As members gear up for the CNBC Investing Club's July Monthly Meeting, we analyze the stocks that soared during the AI rally and those that lost...
AstraZeneca's Trial Setback Sparks Concerns Over Future Pipeline Viability
The disappointing results from AstraZeneca's latest trial raise critical questions about the sustainability of its premium valuation in an...